148 related articles for article (PubMed ID: 20029970)
1. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
3. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
5. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
[TBL] [Abstract][Full Text] [Related]
6. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Kuderer NM; Dale DC; Crawford J; Cosler LE; Lyman GH
Cancer; 2006 May; 106(10):2258-66. PubMed ID: 16575919
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
9. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
[TBL] [Abstract][Full Text] [Related]
10. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT
Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024
[TBL] [Abstract][Full Text] [Related]
11. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
12. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
15. [A 10-year-review (1998 - 2007) on 3449 cases of osteoporotic hip fractures: trend of hospitalization and inpatient costs].
Cheng ZA; Lin DK; Liu DB; Shen HY; Chen Q; Qiu QW; Liu SL
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Nov; 29(11):1128-31. PubMed ID: 19173940
[TBL] [Abstract][Full Text] [Related]
16. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
17. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
18. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Dulisse B; Li X; Gayle JA; Barron RL; Ernst FR; Rothman KJ; Legg JC; Kaye JA
J Med Econ; 2013; 16(6):720-35. PubMed ID: 23452298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
